Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s): N.MMED | N.MMED.WA | N.MMED.WR | N.MMED.WS

Healthcare

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).

NDAQ:MNMD - Post by User

Mind Medicine (MindMed) Inc > Valuation::: Easy $10 👉𓋼🤑𓋼👈 Canopy of Mushroom Space!!

<< Previous

Bullboard Posts

Next >>

Comment by Unimaginativelyon Apr 29, 2021 1:58pm

250 Views

Post# 33094518

RE:Valuation::: Easy $10 👉𓋼🤑𓋼👈 Canopy of Mushroom Space!!

like canopy growth corp? Aye possible. The mushroom giant of the business. I'm in chart looks paved for a massive next level up. Cup and Handle formation ^^^^ I'll take some money off table on next 52 week high. Good luck to all

GajjarDr wrote:
Next-Gen Psychedelic Innovation
MindMed is discovering and researching a broad range of novel compounds, therapies, and technologies with the goal of unlocking new pathways for patients.

Technologies and analytics that seek to personalize psychedelic therapy experiences for a specific patient are imperative to the patient experience. This technology aims to optimize the dosing of MDMA, LSD and other psychedelics based on a patient’s profile. The R&D is taking place in collaboration with the University Hospital Basel’s Liechti Lab, the leading research center focused on the pharmacology of psychedelic substances.